Navigation Links
Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection

- Findings Published in Blood Highlight Millennium Leadership in Personalized Medicine and Could Strengthen the Role of VELCADE as Foundation of Therapy in Broad Range of Multiple Myeloma Patients -

CAMBRIDGE, Mass., April 17, 2007 /PRNewswire-FirstCall/ -- Findings published in the April 15th issue of Blood show that a team of researchers led by Millennium Pharmaceuticals, Inc. has discovered biomarkers which may lead to identifying multiple myeloma patients likely to respond to VELCADE. VELCADE is the U.S. market leading therapy for previously treated multiple myeloma patients with an unsurpassed median survival of 29.8 months as a single agent.

These findings add to the body of evidence that supports the role of VELCADE in the treatment of a broad range of multiple myeloma patients and highlight the applicability of genomics research. This research, in combination with similar ongoing studies, may ultimately lead to improved outcomes for patients.

The identification of these biomarkers was the result of a collaborative effort by researchers from Millennium and leading multiple myeloma academic centers. These centers included Dana-Farber Cancer Institute, Boston; Myeloma Institute of Research and Therapy at the University of Arkansas for Medical Services, Little Rock; Mayo Clinic, Scottsdale; and Department of Hematology, Erasmus Medical Center, Rotterdam.

The combined team performed genomics analyses on tumor samples from multiple myeloma patients in VELCADE clinical trials. These trials included the APEX Phase III study, which demonstrated the superiority of VELCADE over standard-of-care dexamethasone in previously treated multiple myeloma patients and is one of the first and largest prospective randomized trials to include genomics analyses.

Findings from the analyses showed that patients with an increased expression of genes in the NFk-B and adhesion molecule pathways may be mo
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
2. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
3. Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments
4. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
5. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
8. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
9. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
10. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
11. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
Post Your Comments:
(Date:9/30/2014)... LOS ANGELES , Sept. 30, 2014   ... apnea shopping destination , today announced that it now ... ResMed . AirSense CPAPs are the first sleep apnea ... makes it simple and easy to track and share ... the overall effectiveness of their CPAP therapy.  In addition, ...
(Date:9/30/2014)... BRUNSWICK, N.J., Sept. 30, 2014 The ... Kessler Foundation and New Jersey Health Foundation (NJHF) ... and patient care programs has been announced by ... officer of Kessler Foundation and James M. ... "The experience of New Jersey Health ...
(Date:9/30/2014)... -- The Eastern European medical device industry is in ... as new medical-device manufacturers are constantly trying to penetrate ... to reduce the cost incurred for placing their products ... effective means to achieve this target. This research service ... and provides profiles of key distributors in ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3
... DIEGO, Aug. 28 Vical Incorporated,(Nasdaq: VICL ... subject in its,Phase 1 trial of the company,s ... placebo-controlled trial will,evaluate safety, tolerability and immune responses ... 45 at two U.S. clinical sites. "We ...
... such ... infectious-disease outbreaks, SEATTLE, Aug. 28 In ... Fred,Hutchinson Cancer Research Center confirm that the avian influenza A ... within a family in,Indonesia. The findings, by biostatistician Ira M. ...
Cached Medicine Technology:Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza 2Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza 3Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza 4Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006 2Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006 3Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006 4
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... Marshall as a free introduction to SurvivalLife.com along with a ... has caught the attention of Shane Michaels, prompting an investigative ... the most well-known people in the survival and preparation niche, ... with all of the great classes and survival products that ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... is helping people perform better in and out of the ... and memory has caught the attention of Shane Michaels, prompting ... day-to-day grind, fatigue is the reason most people simply just ... whether that means staying focused at work, getting the motivation ...
(Date:9/30/2014)... 30, 2014 VisitandCare.com reports ... has gone up more than 79 percent in 2014, ... company also reported total revenue tripled for its entirety ... company’s professional strategy has allowed them to partner with ... for patient comfort and privacy — with state-of-the-art surgical ...
(Date:9/30/2014)... September 30, 2014 Hospice & ... annual “In Celebration” gala, honoring three outstanding individuals ... of striving to provide extraordinary and dignified comfort, ... a serious or life-limiting illness. , The event ... Rye, NY and recognized William (Bill) J. McGuinness, ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set to open ... RMS welcomes the launch of an entirely new facility, ... new treatment center for the Lung Institute. , ... Nashville, the hope is to bring awareness to those ... undiagnosed. With Nashville being a hub for medical technology, ...
Breaking Medicine News(10 mins):Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Regenerative Medicine Solutions Expanding 2
... have covered one-third of the country's children in a ... than 11 million children in 1,301 counties of central ... hepatitis B, said Jiang Zuojun, the Vice-Minister for Health. ... their pace to reach the remaining two-thirds by the ...
... incidence of breast cancer at Brisbane's ABC headquarters at Toowong ... ,ABC managing director Mark Scott said that Dr Joanne Aitken ... by Dr Bruce Armstrong. ,Mr Scott added that ... alongside the panel. ,The review panel was established ...
... The British government's drug watchdog has warned yesterday that the doctors ... bipolar disorder in spite of it being one of the most ... are waiting on an average for eight years to be accurately ... almost 20 years of ill health, of which they might not ...
... poll that was conducted by the nursing union of the ... and harassment a continuing problem in// healthcare. ,Stating ... have suffered abuse from fellow staff and managers over the ... those bullied had wanted changes in their work so as ...
... Industry (ABPI) and the BioIndustry Association (BIA) recommended new ... with extreme care and caution while testing pioneering drugs. ... March left six volunteers in the state of coma. ... The new drug was tested at the Parexel trial ...
... studies shows that alternative and complementary therapies may have ... menopause.// The review article is published in the July ... the JAMA/Archives journals. ,Twenty-five million women will ... of them will experience hot flashes, night sweats, vaginal ...
Cached Medicine News:Health News:Breast Cancer Review Panel Adds Two Experts 2Health News:Bipolar Disorder Not Being Accurately Diagnosed By Doctors In UK 2Health News:Alternative Therapies May Not Ease Menopause Symptoms 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: